A Study to Compare Efficacy and Safety of CT-P55 and Cosentyx in Patients with Moderate to Severe Psoriasis

Launched by CELLTRION · Oct 7, 2024

Keywords

ClinConnect Summary

This clinical trial is looking to see how effective and safe a new medication called CT-P55 is compared to an existing treatment known as Cosentyx for people with moderate to severe plaque psoriasis. Plaque psoriasis is a skin condition that causes red, scaly patches to appear on the skin, and this study aims to find out which treatment works better for patients.

To participate in the trial, patients must have been diagnosed with chronic plaque psoriasis for at least 24 weeks. However, individuals who have other types of psoriasis or who have previously received certain other treatments that target the immune system will not be eligible. The trial is currently not recruiting participants, but when it does, those who qualify can expect to receive either CT-P55 or Cosentyx under careful monitoring to help researchers understand how well each treatment works and how safe they are. If you or a loved one have been living with this condition, this trial could provide a chance to explore new treatment options.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • - Patient has had a diagnosis of chronic plaque psoriasis for at least 24 weeks.
• Exclusion Criteria:
• • Patient diagnosed with forms of psoriasis other than chronic plaque-type or medication-induced psoriasis.
• • Patient who has previously received Secukinumab or any other biologic drug directly targeting Interleukin-17 or the IL-17 receptor.
• • Patient who has allergies to any of the excipients of study drug or materials of device or any other murine and human proteins, or patient with a hypersensitivity to immunoglobulin products.